310569
All or Nothing? Compromise and Consistency in Public Health Jurisprudence
By contrast, a wide variety of legal doctrines under which public health policies are evaluated put a premium on consistency. In the administrative law context, for example, an appellate court recently invalidated New York City’s beverage portion size rule in part because it did not apply equally to all categories of retailers. In international trade law, the U.S. was found to have violated WTO commitments by banning clove cigarettes but not menthol cigarettes. And in the First Amendment context, courts have invalidated marketing restrictions that make “speaker-based” distinctions between categories of businesses. All of these doctrines push public health regulation towards “all or nothing” approaches—the government must regulate extensively or not at all.
This presentation will use these recent examples to explore the tension between compromise and consistency in public health jurisprudence and the dangers that an implicit “all-or-nothing” rule poses to public health and to the political process more generally.
Learning Areas:
Public health or related laws, regulations, standards, or guidelinesPublic health or related public policy
Learning Objectives:
Describe the benefits of compromise and incrementalism in public health policymaking.
Describe how legal doctrines in public health emphasize consistency and penalize incrementalism.
Analyze the implications of recent legal decisions that push the government towards "all-or-nothing" approaches to policymaking.
Keyword(s): Law, Theory
Qualified on the content I am responsible for because: I am an assistant professor of law and public health at Ohio State University. I have previously directed centers that worked with state and local governments on tobacco control and chronic disease prevention policy, and I have assisted in litigation defending local, state, and federal public health laws.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.